Transaction #38206 · Form 4 · 0001727606-26-000007
NEUROCRINE BIOSCIENCES INC · Stock award · Stock Option
NEUROCRINE BIOSCIENCES INC · Transacted November 4, 2026 · Filed November 5, 2026
What does this filing report?
An SEC Form 4 filing for NEUROCRINE BIOSCIENCES INC records a stock award involving Stock Option on November 4, 2026. The reported quantity was 8,314. The filing date is November 5, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- NEUROCRINE BIOSCIENCES INC
- Company CIK
- 0000914475
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 8,314
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 8,314
- Ownership description
- Not reported
- SEC acceptance time
- Nov 5, 2026, 4:10 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- ROBERTS EIRY ↗
Chief Medical Officer
CIK 0001727606
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 8,314
- Conversion / exercise price
- 166.05
- Exercise date
- Not reported
- Expiration date
- November 4, 2036
Filing footnotes & remarks
- F1
- Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on December 4, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F2
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F3
- The Restricted Stock Units will settle annually at 1/4 of the units settling on each of November 4, 2027, November 4, 2028, November 4, 2029, and November 4, 2030.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.